Critical review of the Appropriate Use Criteria for amyloid imaging: Effect on diagnosis and patient care
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Introduction: The utility of the Appropriate Use Criteria (AUC) for amyloid imaging is not established. Methods: Fifty‐three cognitively impaired patients with clinical F 18‐florbetapir imaging were classified as early and late onset, as well as AUC‐consistent or AUC‐inconsistent. Chi‐square statistics and t test were used to compare demographic characteristics and clinical outcomes as appropriate. Results: Early‐onset patients were more likely to be amyloid positive. Change in diagnosis was more frequent in late‐onset cases. Change in therapy was more common in early‐onset cases. AUC‐consistent and AUC‐inconsistent cases had comparable rates of amyloid positivity. We saw no difference in the rate of treatment changes in the AUC‐consistent group as opposed to the AUC‐inconsistent group. Discussion: The primary role of amyloid imaging in the early‐onset group was to confirm the clinically suspected etiology, and in the late‐onset group in detecting amyloid‐negative cases. The rate of therapeutic changes was significantly greater in the early‐onset cases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Use of Florbetapir-PET for Imaging β-Amyloid Pathology
Clark, C. M. (2011) · JAMA · doi:10.1001/jama.2010.2008 · Cited by 1,117
Beach, T. G., Monsell, S. E., Phillips, L. E., & Kukull, W. (2012) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e31824b211b · Cited by 1,103 · cited 4×
“The major drawbacks cited by insurance carriers are (1) imperfect specificity [2], (2) ethical concern that cognitively normal individualsmight be inappropriately scanned (i.”
BackgroundResultInfluentialClark, C. M., Pontecorvo, M. J., Beach, T. G., Bedell, B. J., Coleman, R. E., Doraiswamy, P. M., Fleisher, A. S., Reiman, E. M., Sabbagh, M. N., Sadowsky, C. H., et al. (2012) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70142-4 · Cited by 855
Prevalence of Amyloid PET Positivity in Dementia Syndromes: A Meta-analysis
Ossenkoppele, R., Jansen, W. J., Rabinovici, G. D., Knol, D. L., van der Flier, W. M., van Berckel, B. N. M., Scheltens, P., Visser, P. J., Verfaillie, S. C. J., Zwan, M. D., et al. (2015) · JAMA · doi:10.1001/jama.2015.4669 · Cited by 677
Self-citationFlorbetaben PET imaging to detect amyloid beta plaques in Alzheimer's disease: Phase 3 study
Sabri, O., Sabbagh, M. N., Seibyl, J., Barthel, H., Akatsu, H., Ouchi, Y., Senda, K., Murayama, S., Ishii, K., Takao, M., et al. (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2015.02.004 · Cited by 602 · cited 1×
“Introduction accuracy of clinical diagnosis compared to the gold standard Alzheimer’s disease (AD) is the most common neurodegenerative disorder and the sixth most common cause of death in the United States [1].”
BackgroundKlunk, W. E., Wang, Y., Huang, G.-F., Debnath, M. L., Holt, D. P., & Mathis, C. A. (2001) · Life Sciences · doi:10.1016/s0024-3205(01)01232-2 · Cited by 457
Fleisher, A. S. (2011) · Archives of Neurology · doi:10.1001/archneurol.2011.150 · Cited by 364
Curtis, C., Gamez, J. E., Singh, U., Sadowsky, C. H., Villena, T., Sabbagh, M. N., Beach, T. G., Duara, R., Fleisher, A. S., Frey, K. A., et al. (2015) · JAMA Neurology · doi:10.1001/jamaneurol.2014.4144 · Cited by 332 · cited 1×
“Introduction accuracy of clinical diagnosis compared to the gold standard Alzheimer’s disease (AD) is the most common neurodegenerative disorder and the sixth most common cause of death in the United States [1].”
BackgroundImpact of molecular imaging on the diagnostic process in a memory clinic
Ossenkoppele, R., Prins, N. D., Pijnenburg, Y. A. L., Lemstra, A. W., van der Flier, W. M., Adriaanse, S. F., Windhorst, A. D., Handels, R. L. H., Wolfs, C. A. G., Aalten, P., et al. (2013) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2012.07.003 · Cited by 194 · cited 1×
“[17] scanned a mix of early- and lateonset patients recruited from the outpatient clinics of the VU Medical Center in the Netherlands with Pittsburgh compound B.”
Method
Cited by
Chételat, G., Arbizu, J., Barthel, H., Garibotto, V., Law, I., Morbelli, S., van de Giessen, E., Agosta, F., Barkhof, F., Brooks, D. J., et al. (2020) · The Lancet Neurology · doi:10.1016/s1474-4422(20)30314-8 · Cited by 526
Self-citationImaging tau and amyloid-β proteinopathies in Alzheimer disease and other conditions
Villemagne, V. L., Doré, V., Burnham, S. C., Masters, C. L., & Rowe, C. C. (2018) · Nature Reviews Neurology · doi:10.1038/nrneurol.2018.9 · Cited by 441
Blennow, K., Shaw, L. M., Stomrud, E., Mattsson, N., Toledo, J. B., Buck, K., Wahl, S., Eichenlaub, U., Lifke, V., Simon, M., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-54204-z · Cited by 192
Fantoni, E. R., Chalkidou, A., O’ Brien, J. T., Farrar, G., & Hammers, A. (2018) · Journal of Alzheimer’s Disease · doi:10.3233/jad-171093 · Cited by 68
Hellwig, S., Frings, L., Bormann, T., Vach, W., Buchert, R., & Meyer, P. T. (2019) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-018-4111-3 · Cited by 32
“This translates into a change in diagnoses in about 20– 30% (range 9–67%) of all patients [4–16], in which the lower and upper ranges of observed frequencies of change were found in patients with early onset or from research populations (few uncertain diagnoses) [4, 16] and in patients with late onset or a particularl…”
BackgroundInfluential
Metadata
- Authors
- Apostolova, L. G., Haider, J. M., Goukasian, N., Rabinovici, G. D., Chételat, G., Ringman, J. M., Kremen, S., Grill, J. D., Restrepo, L., Mendez, M. F., & Silverman, D. H.
- Venue
- Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring
- Publisher
- Wiley
- Published
- 2016-01
- Volume
- 5
- Issue
- 1
- Pages
- 15-22
- ISSN
- 2352-8729 (ISSN-L)
- OpenAlex
- W2562968451
- Cited by
- 39
- References
- 9
- FWCI
- 5.43
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.